Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopamine versus saline crossover study of peripheral chemoreflex blockade in pulmonary arterial hypertension
ACTRN12622000505707Phase 4Completed
- Sponsor
- The University of Auckland
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of dopamine in pulmonary arterial hypertension (PAH) (2 arms), sponsored by The University of Auckland. Primary endpoints: Dyspnoea intensity, Exercise endurance time and 1 more. Started Jun 2023; status: completed.
02
Drugs
dopamine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ACTRN12622000505707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000505707.